{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:43:38Z","timestamp":1790963018023,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Single inhaler triple therapy is widely used in Chronic Obstructive Pulmonary Disease (COPD) and asthma. This research aimed to analyze adverse events (AEs) associated with Budesonide\/Glycopyrronium\/Formoterol Fumarate (BUD\/GLY\/FOR) and Fluticasone Furoate\/Umeclidinium\/Vilanterol (FF\/UMEC\/VI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a cross-sectional study. BUD\/GLY\/FOR (2020Q3-2024Q3) and FF\/UMEC\/VI (2018Q1-2024Q3) report files were downloaded from the U.S. Food and Drug Administration\u2019s (FDA) Adverse Event Reporting System (FAERS) database. We use reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) for disproportionality analysis. The aim was to explore associations between drugs and preferred term (PT) and system organ classification (SOC) levels. We focused on exploring the top 10 PTs of each drug\u2019s BCPNN (IC) effect value and the PT of pneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>16,355 AEs in BUD\/GLY\/FOR and 39,110 AEs in FF\/UMEC\/VI were extracted. Device use issues, oropharyngeal and vocal problems, pneumonia, <jats:italic>candida<\/jats:italic> infections, and urinary retention were the standard PTs present in drug leaflets. The risk of device use issues was higher in BUD\/GLY\/FOR, whereas the risk of pneumonia and <jats:italic>candida<\/jats:italic> infection in FF\/UMEC\/ VI had higher risk. Outside of the drug leaflets, both drugs were associated with a higher risk of AEs in vascular disorders. BUD\/GLY\/FOR group had a higher risk of AEs in body height decreased and hypoacusis. Notably, this study found an association between the above PTs and drugs, and the causal relationship needs to be verified by further longitudinal studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study provides a preliminary exploration of the safety of clinical use of BUD\/GLY\/FOR and FF\/UMEC\/VI, and clinicians should be alert to potential adverse effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1460407","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T06:13:37Z","timestamp":1736403217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhishen","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"B1","unstructured":"Global initiative for chronic obstructive lung disease - GOLD\n          \n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1056\/NEJM200010123431502","article-title":"Effect of long-term treatment with inhaled budesonide on adult height in children with asthma","volume":"343","author":"Agertoft","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"CD010126","DOI":"10.1002\/14651858.CD010126.pub2","article-title":"Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth","volume":"6","author":"Axelsson","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1007\/s12325-021-01703-z","article-title":"Efficacy and safety of budesonide\/glycopyrronium\/formoterol fumarate versus other triple combinations in COPD: a systematic literature review and network meta-analysis","volume":"38","author":"Bourdin","year":"2021","journal-title":"Adv. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","article-title":"Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA)","volume":"26","author":"Brown","year":"2003","journal-title":"Drug Saf."},{"key":"B6","unstructured":"BREZTRI- budesonide, glycopyrrolate, and formoterol fumarate aerosol, metered"},{"key":"B7","unstructured":"TRELEGY ELLIPTA-fluticasone furoate, umeclidinium bromide and vilanterol trifenatate powder"},{"key":"B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.rmed.2016.09.015","article-title":"Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device","volume":"120","author":"Dekhuijzen","year":"2016","journal-title":"Respir. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1513\/AnnalsATS.202002-096OC","article-title":"Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT","volume":"18","author":"Dransfield","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101873","DOI":"10.1016\/j.pupt.2019.101873","article-title":"Pharmacokinetics of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD","volume":"60","author":"Dunn","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B11","unstructured":"Highlights of prescribing information for Trelegy ELLIPTA\n          \n          \n          2017"},{"key":"B12","volume-title":"Highlights of prescribing information","year":"2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.14309\/ajg.0000000000000374","article-title":"Reporting adverse drug events","volume":"114","author":"Feagins","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1007\/s12325-020-01311-3","article-title":"Efficacy of budesonide\/glycopyrronium\/formoterol fumarate metered dose inhaler (bgf mdi) versus other inhaled corticosteroid\/long-acting muscarinic antagonist\/long-acting \u03b22-agonist (ICS\/LAMA\/LABA) triple combinations in COPD: a systematic literature review and network meta-analysis","volume":"37","author":"Ferguson","year":"2020","journal-title":"Adv. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","article-title":"Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s40265-021-01562-6","article-title":"Budesonide\/glycopyrronium\/formoterol: a review in COPD","volume":"81","author":"Heo","year":"2021","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1007\/s12325-022-02231-0","article-title":"Fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis","volume":"39","author":"Ismaila","year":"2022","journal-title":"Adv. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"f3306","DOI":"10.1136\/bmj.f3306","article-title":"Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting \u03b22 agonist: observational matched cohort study (PATHOS)","volume":"346","author":"Janson","year":"2013","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1574886318666230228142856","article-title":"Identification of signal of clindamycin associated renal failure acute: a disproportionality analysis","volume":"19","author":"Javed","year":"2024","journal-title":"Curr. Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2147\/COPD.S400707","article-title":"Cost-effectiveness of single-inhaler triple therapy (FF\/UMEC\/VI) versus tiotropium monotherapy in patients with symptomatic moderate-to-very severe COPD in the UK","volume":"18","author":"Kendall","year":"2023","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1002958","DOI":"10.1371\/journal.pmed.1002958","article-title":"Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis","volume":"16","author":"Lee","year":"2019","journal-title":"PLoS Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"106807","DOI":"10.1016\/j.rmed.2022.106807","article-title":"Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: a real-world study","volume":"197","author":"Mannino","year":"2022","journal-title":"Respir. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ethos trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00408-024-00677-3","article-title":"Cardiovascular events with the use of long-acting muscarinic receptor antagonists: an analysis of the FAERS database 2020-2023","volume":"202","author":"Matera","year":"2024","journal-title":"Lung"},{"key":"B28","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00405-009-1141-2","article-title":"Evaluation of laryngeal findings in users of inhaled steroids","volume":"267","author":"Ozbilen","year":"2010","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.2147\/COPD.S366765","article-title":"Cost-effectiveness of once-daily single-inhaler COPD triple therapy in Spain: IMPACT trial","volume":"17","author":"Paly","year":"2022","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1081-1206(10)60711-9","article-title":"Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis","volume":"98","author":"Rachelefsky","year":"2007","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B31","unstructured":"global initiative for asthma - GINA\n          \n          \n          2024"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.3390\/jcm11154491","article-title":"Comparing the efficacy and safety profile of triple fixed-dose combinations in COPD: a meta-analysis and IBiS score","volume":"11","author":"Rogliani","year":"2022","journal-title":"J. Clin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.cmi.2022.11.029","article-title":"Hospitalization for chronic obstructive pulmonary disease and pneumonia: association with the dose of inhaled corticosteroids. A nation-wide cohort study of 52 100 outpatients","volume":"29","author":"R\u00f8nn","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"B34","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"B36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12325-022-02346-4","article-title":"Adverse events reported with therapies targeting the cgrp pathway during the first 6 Months post-launch: a retrospective analysis using the FDA adverse events reporting system","volume":"40","author":"Silberstein","year":"2023","journal-title":"Adv. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/0976-500X.162004","article-title":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use","volume":"6","author":"Singh","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12931-023-02534-y","article-title":"Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging","volume":"24","author":"Usmani","year":"2023","journal-title":"Respir. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","article-title":"Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials","volume":"394","author":"Virchow","year":"2019","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.2147\/COPD.S139035","article-title":"Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist","volume":"12","author":"Yang","year":"2017","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"CD002991","DOI":"10.1002\/14651858.CD002991.pub3","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","volume":"3","author":"Yang","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B44","doi-asserted-by":"publisher","first-page":"CD009471","DOI":"10.1002\/14651858.CD009471.pub2","article-title":"Inhaled corticosteroids in children with persistent asthma: effects on growth","volume":"2014","author":"Zhang","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"713258","DOI":"10.3389\/fpubh.2021.713258","article-title":"Cost-effectiveness analysis of triple combination preparations in the treatment of moderate-to-severe chronic obstructive pulmonary disease","volume":"9","author":"Zhou","year":"2021","journal-title":"Front. Public Health"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1460407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T06:13:43Z","timestamp":1736403223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1460407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":46,"alternative-id":["10.3389\/fphar.2024.1460407"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1460407","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"article-number":"1460407"}}